Blocking Synaptogenesis For Chronic Pain Management

Tech ID: 30526 / UC Case 2019-679-0

Brief Description

Gabapentin is used for treatment of seizures and hypersensitivity to pain. Researchers at UCI have employed low-dosage gabapentin immediately after injury to block the development of chronic pain.

Suggested uses

Expanding beyond currently approved use for seizures and neuralgia to include use as a preventative treatment for chronic pain

Features/Benefits

·Gabapentin can successfully block the development of chronic pain

·Reduce reliance on opioids as a method to treat chronic pain

Full Description

Chronic pain is one of the leading causes of disability in the United States, with an estimated 30% of adults experiencing chronic pain. Many therapeutics have been released to help minimize the pain such as gabapentinoids, which bind to calcium channels in the spinal cord, thus blocked the exaggerated excitation and hypersensitivity that lead to the development of new connections between nerves to cause chronic pain. However, the optimal dosage or timing of this treatment has not been discovered. Work by scientists at UCI have shown that a repurposed the anti-convulsant, Gabapentin, can block the hypersensitivity that leads to chronic pain in a dose-dependent manner. Additionally, gabapentin has been shown to effectively block, but not reverse chronic-pain related changes, indicating that it is best used in a preventative fashion.

State Of Development

Gabapentin has been approved by the FDA for treatment of seizures and neuralgia. Gabapentin has been tested by Lou and colleagues for prevention of chronic pain in rodent models.

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Luo, Zhigang D.

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2019, The Regents of the University of California
Terms of use | Privacy Notice